Focused ultrasound is an early-stage, non-invasive therapeutic technology with the potential to transform the treatment of many medical disorders by using ultrasonic energy to target tissue deep in the body without incisions or radiation.
Focused ultrasound is the marriage of two innovative technologies:
- focused ultrasound—which provides the energy to treat tissue deep in the body precisely and noninvasively, and
- magnetic resonance or ultrasound imaging—which is used to identify and target the tissue to be treated, guide and control the treatment in real time, and confirm the effectiveness of the treatment.
The fundamental principle is analogous to using a magnifying glass to focus beams of sunlight on a single point to burn a hole in a leaf. With focused ultrasound, an acoustic lens is used to concentrate multiple intersecting beams of ultrasound on a target deep in the body with extreme precision and accuracy. Depending on the design of the lens and the ultrasound parameters, the target can be as small as 1×1.5mm or as large as 10x16mm in diameter.
Where each of the individual beams passes through the tissue, there is no effect. But, at the focal point, the convergence of the multiple beams of focused ultrasound energy results in many important biological effects, creating the possibility of treating a variety of medical disorders. Read more about the mechanisms of actions.
Focused ultrasound treatments can be performed on an outpatient basis, require no incisions,
FUSHK Website Content – Draft 062121
and can result in minimal discomfort and few complications, allowing for rapid recovery.
Alicia García Herrero, PhD – Director
Alicia García Herrero, PhD, is chief economist for Asia Pacific at the French investment bank Natixis. Based in Hong Kong, Dr. García Herrero is also an independent Board Member of AGEAS insurance group and adjunct professor at the Hong Kong University of Science and Technology. She is a Senior Fellow at both the European think-tank BRUEGEL and the East Asian Institute of the National University Singapore. Throughout her career in economics, Dr. García Herrero has held positions at leading international banks, including Banco Bilbao Vizcaya Argentaria, the Bank of International Settlements, the Bank of Spain, the European Central Bank, Banco Santander, and the International Monetary Fund. She has also been a visiting professor at Johns Hopkins University, China Europe International Business School, and Universidad Carlos III de Madrid. She holds a PhD in economics from George Washington University and has published extensively in refereed journals and books.
Oliver Weisberg – Director
Oliver Weisberg is the Chief Executive Officer of Blue Pool Capital, a multi-strategy investment firm based in Hong Kong. Mr. Weisberg is an Alternate Governor of the Brooklyn Nets and New York Liberty, and Vice Chairman of BSE Global. Mr. Weisberg graduated from Harvard College and spent considerable time living and doing business in Mainland China. He is a fluent Chinese speaker. Mr. Weisberg started on Wall Street in New York and built his career in private equity, special situations, and hedge fund investing in Asia. He was part of Goldman Sachs’ Asian Special Situations and Principal Investment Area divisions, where he represented the firm’s investment in Alibaba and sat on the Alibaba board. In 2006, Mr. Weisberg joined Citadel and was a Partner in Hong Kong when he left to join Blue Pool Capital in 2015. Mr. Weisberg manages the firm’s investments in the Brooklyn Nets, New York Liberty, San Diego Seals, Premier Lacrosse League, and Los Angeles FC. Mr. Weisberg played competitive tennis in high school and was a walk on to the Harvard Squash team. For over a decade, Mr. Weisberg was on the board and instrumental in helping to build Teach for China; he is currently on the Advisory Board of the Harvard University Shanghai Center and the Harvard China Fund. Mr. Weisberg serves on the board of Squash + Education Alliance (SEA). He is a member of the Young Presidents’ Organization and the Confrerie des Chevaliers du Tastevin.